Cancer drug trial for tough lymphoma halted early – what we know
NCT ID NCT04362007
First seen Mar 22, 2026 · Last updated May 15, 2026 · Updated 7 times
Summary
This study tested an experimental drug called ASTX660 in people with certain types of T-cell lymphoma that had returned or stopped responding to standard treatments. The trial was stopped early after enrolling only 8 participants. The main goals were to check the drug's safety and find the best dose, but no results are available yet.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RELAPSED OR REFRACTORY PERIPHERAL T-CELL LYMPHOMA(PTCL),CUTANEOUS T-CELL LYMPHOMA(CTCL),ADULT T-CELL LEUKEMIA/LYMPHOMA(ATLL) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Yamagata University Hospital
Yamagata, Japan
Conditions
Explore the condition pages connected to this study.